Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(123 produits)
- CSF-1R(42 produits)
- EGFR(591 produits)
- Récepteur Ephrin(23 produits)
- FLT(87 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(173 produits)
- SON(4 produits)
- Hck(3 produits)
- IGF-1R(102 produits)
- PDGFR(126 produits)
- PYK2(7 produits)
- Src(81 produits)
- Récepteur TAM(33 produits)
- Tie-2(20 produits)
- Récepteur Trk(59 produits)
- Tyrosine Kinases(25 produits)
- VEGFR(253 produits)
- c-Fms(111 produits)
- c-Kit(113 produits)
- c-Met/HGFR(134 produits)
- c-RET(56 produits)
Affichez 13 plus de sous-catégories
1259 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC Her3-binding moiety 2
CAS :PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formule :C25H25N7O2Couleur et forme :SolidMasse moléculaire :455.51EGFR-IN-132
CAS :EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58SORT1-IN-5
CAS :SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formule :C19H31NO6SCouleur et forme :SolidMasse moléculaire :401.52EGFR-IN-133
CAS :<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56c-Met-IN-2
CAS :c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Formule :C24H21FN10ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :484.49Anticancer agent 109
CAS :Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].Formule :C19H15N3O2Couleur et forme :SolidMasse moléculaire :317.34EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375MerTK-IN-3
CAS :MerTK-IN-3 (compound 11) is an orally active, selective inhibitor of MerTK, exhibiting IC50 values of 21.5 nM for MerTK and 991.3 nM for Tyro3. It is applicable in colon cancer research.Formule :C36H31FN8O4Couleur et forme :SolidMasse moléculaire :658.68BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331ES-072
CAS :<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45BPI-15086
CAS :<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Formule :C29H33ClN8O4Couleur et forme :SolidMasse moléculaire :593.08NMS-P626
CAS :<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Formule :C28H35F2N7O4SCouleur et forme :SolidMasse moléculaire :603.68Neptinib
CAS :<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.90HS-345
CAS :<p>HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.</p>Formule :C19H18N6O2SCouleur et forme :SolidMasse moléculaire :394.45ONO-7579
CAS :<p>ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.</p>Formule :C24H18ClF3N6O4SCouleur et forme :SolidMasse moléculaire :578.95SST0116CL1
CAS :<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formule :C22H31ClN4O6Couleur et forme :SolidMasse moléculaire :482.96ROS1-IN-2
CAS :<p>ROS1-IN-2 (Compound 3), a ROS1 inhibitor, is utilized in cancer research.</p>Formule :C29H37ClN5O2PCouleur et forme :SolidMasse moléculaire :554.06Tyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183TrkA-IN-9
CAS :<p>TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.</p>Formule :C31H32N4O4Couleur et forme :SolidMasse moléculaire :524.61KRC-00715
CAS :<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Formule :C25H25F3N8O3Couleur et forme :SolidMasse moléculaire :542.51EGFR-IN-23
CAS :EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68AZ8010
CAS :AZ8010 (AZ12908010) serves as an effective inhibitor of FGFR1-3 and exhibits antiproliferative properties, making it useful for cancer research.Formule :C27H34N4O3Couleur et forme :SolidMasse moléculaire :462.58TRK-IN-26
CAS :<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Formule :C30H22F2N6O4Couleur et forme :SolidMasse moléculaire :568.53EGFR-IN-126
CAS :<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45FMP-API-1
CAS :FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).Formule :C13H14N2O2Couleur et forme :SolidMasse moléculaire :230.262PF-06273340
CAS :<p>PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。</p>Formule :C23H22ClN7O3Degré de pureté :98% - 98.00%Couleur et forme :SolidMasse moléculaire :479.92EGFR-IN-35
CAS :EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96TrkC-IN-1
CAS :TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395D-69491 hydrochloride
CAS :D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formule :C25H26Cl2FN7O3Couleur et forme :SolidMasse moléculaire :562.42JBJ-09-063
CAS :JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65Si306
CAS :Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formule :C25H26BrClN6OSCouleur et forme :SolidMasse moléculaire :573.94Protein kinase inhibitor 4
CAS :<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Formule :C25H24F2N6O3SMasse moléculaire :526.56DDR1/2 inhibitor-3
CAS :<p>DDR1/2 inhibitor-3 (5n) is an inhibitor of DDR1/2, with IC50 values of 9.4 nM and 20.4 nM, respectively. It is applicable in anti-inflammatory research.</p>Formule :C31H31F3N6OCouleur et forme :SolidMasse moléculaire :560.613AZ12601011
CAS :<p>AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.</p>Formule :C19H15N5Degré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :313.36Zotizalkib
CAS :<p>TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.</p>Formule :C21H20F3N5O3Degré de pureté :98.7%Couleur et forme :SolidMasse moléculaire :447.41Vecabrutinib
CAS :<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Formule :C22H24ClF4N7O2Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :529.92Enbezotinib
CAS :Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formule :C21H21FN6O3Degré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :424.43AGL-2263
CAS :AGL-2263 is a blocker of insulin receptor (IR)Formule :C17H10N2O5Couleur et forme :SolidMasse moléculaire :322.27EGFR-IN-7
CAS :<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formule :C32H41BrN9O2PDegré de pureté :95.32% - 99.64%Couleur et forme :SolidMasse moléculaire :694.6HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Couleur et forme :Odour LiquidTLC9995-0188
CAS :Tyrosine-protein kinase ABL, IC50: 1500 nMFormule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331Tyrosine kinase inhibitor
CAS :<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Formule :C31H31FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.61Nimotuzumab (powder)
CAS :<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Couleur et forme :LiquidOlmutinib
CAS :Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormule :C26H26N6O2SDegré de pureté :99.14%Couleur et forme :SolidMasse moléculaire :486.59Duligotuzumab
CAS :<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Degré de pureté :95%Couleur et forme :LiquidEGFR-IN-82
CAS :<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formule :C32H41BrN9O2PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :694.6FGFR1 inhibitor-10
CAS :<p>FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation.</p>Formule :C26H30F3N7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :561.62Trk-IN-4
CAS :Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.Formule :C24H23F4N5O4Degré de pureté :98.13%Couleur et forme :SolidMasse moléculaire :521.46Syk-IN-8
CAS :<p>Syk-IN-8 (compound 19q) functions as a Syk inhibitor with demonstrated antiproliferative effects on a variety of hematological tumor cells.</p>Formule :C23H26N10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.52JDB175
CAS :<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Formule :C26H21F3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.47Canlitinib
CAS :<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61BTK-IN-25
CAS :<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Formule :C28H27F2N3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :523.53TrkB-IN-1
CAS :<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formule :C19H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :368.34YK-029A
CAS :<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formule :C27H32N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.6BTK-IN-27
CAS :<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Formule :C31H35N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :537.66APG-2449
CAS :<p>APG-2449 is an orally active inhibitor targeting ALK, ROS1, and FAK, demonstrating antitumor efficacy in mouse models of non-small cell lung cancer (NSCLC) [1].</p>Formule :C33H42ClN5O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.24EGFR-IN-123
CAS :<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formule :C24H27F3N6OCouleur et forme :SolidMasse moléculaire :472.51EGFR-IN-122
CAS :<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formule :C19H20N4O3Couleur et forme :SolidMasse moléculaire :352.39
